AHA 2020

American Heart Association’s Scientific Sessions

Monkey model of COVID-19 myocardial injury

Polypill plus aspirin for primary prevention of cardiovascular events

IV Iron slashes HF hospitalisations by 26%

Dapagliflozin reduces renal risk independent of CV disease status

Sotatercept improves right ventricular-pulmonary arterial coupling and right ventricular function

Mavacamten effective in obstructive hypertrophic cardiomyopathy

Clever trial design gets patients back on statins: the SAMSON trial

PIONEER III trial: Drug-eluting stents are comparable

AF screening benefit: the mHealth Screening to Prevent Strokes (mSTOPS) study

Sotagliflozin shows cardiorenal benefits in diabetes patients: 2 trials

Children exposed to tobacco smoke have worse heart function as adults

Extra imaging for women with heart attacks without blockage

Finerenone lowers CV events in diabetic CKD patients

Obese patients 50 years or younger have worse COVID-19 outcomes

No benefit from high-dose omega-3 for AF high-risk patients

Cardiovascular disease on outcomes among hospitalised COVID-19 patients

Lowering LDL cholesterol in older patients is beneficial

Transgender people have unaddressed heart disease risks

Top image: @ iStockPhoto: Noctiluxx

The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.